Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Efgartigimod in Sjögren-Larsson Syndrome. The expected timing is based on the latest available company guidance and may change.
RHO Ph2 & UNITY trials. 3/27/24 Top-line Ph2 data. 6/11/25- Presented new Ph2 data at EULAR '25. Ph3 trial ongoing. 01/12/26:- UNITY topline data in H2 2027. 06/03/26:- RHO+ Week 72 OLE data presented at EULAR 2026. UNITY Ph3 topline results expected H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.